Janus-like effects of type I interferon in autoimmune diseases.
Janus-like effects of type I interferon in autoimmune diseases.
复制标题
DOI：
10.1111/j.1600-065x.2012.01131.x
复制
发表时间：
2012-07
影响因子：
8.7
通讯作者：
Raman C
中科院分区：
文献类型：
--
作者：
Axtell RC;Raman C
在多发性硬化症中，I型干扰素（IFN）被认为是免疫调节性的，重组形式的IFN-β是这种疾病最常用的治疗方法。这与大多数其他自身免疫性疾病相反，因为I型IFN有助于病理学。即使在复发-缓解型多发性硬化症（RRMS）人群中，30-50%的MS患者对这种治疗无反应，并且它始终是视神经肌萎缩症（NMO），一种类似于RRMS的疾病。在这篇文章中，我们讨论了自身免疫领域的最新进展，并介绍了解释I型IFN如何在主要由Th 17应答驱动的疾病中具有促炎性，以及当疾病主要是Th 1时具有治疗性的理论。
In multiple sclerosis, type I interferon (IFN) is considered immune-modulatory, and recombinant forms of IFN-β are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, since type I IFN contributes to the pathologies. Even within the relapsing-remitting multiple sclerosis (RRMS) population, 30–50% of MS patients are nonresponsive to this treatment and it consistently worsens neuromyelitis optica (NMO), a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro-inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.